WallStreetZenWallStreetZen

NASDAQ: XAIR
Beyond Air Inc Stock Forecast, Predictions & Price Target

Analyst price target for XAIR

Based on 1 analyst offering 12 month price targets for Beyond Air Inc.
Min Forecast
$10.00+681.25%
Avg Forecast
$10.00+681.25%
Max Forecast
$10.00+681.25%

Should I buy or sell XAIR stock?

Based on 1 analyst offering ratings for Beyond Air Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their XAIR stock forecasts and price targets.

XAIR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-14

1 of 1

Forecast return on equity

Is XAIR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is XAIR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

XAIR revenue forecast

What is XAIR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$12.8M+1,760.67%
Avg 2 year Forecast
$40.8M+5,824.53%
Avg 3 year Forecast
$87.1M+12,540.06%
XAIR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

XAIR revenue growth forecast

How is XAIR forecast to perform vs Medical Devices companies and vs the US market?
Company
395.4%
Industry
8.29%
Market
10.08%
XAIR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
XAIR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

XAIR vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
XAIR$1.28$10.00+681.25%Strong Buy
CTSO$0.82$1.00+21.65%Hold
NSYS$17.39N/AN/A
IRIX$2.94N/AN/A
RBOT$0.27$0.67+144.32%Hold

Beyond Air Stock Forecast FAQ

Is Beyond Air Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: XAIR) stock is to Strong Buy XAIR stock.

Out of 1 analyst, 1 (100%) are recommending XAIR as a Strong Buy, 0 (0%) are recommending XAIR as a Buy, 0 (0%) are recommending XAIR as a Hold, 0 (0%) are recommending XAIR as a Sell, and 0 (0%) are recommending XAIR as a Strong Sell.

If you're new to stock investing, here's how to buy Beyond Air stock.

What is XAIR's revenue growth forecast for 2025-2027?

(NASDAQ: XAIR) Beyond Air's forecast annual revenue growth rate of 395.4% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Beyond Air's revenue in 2024 is $689,000.On average, 2 Wall Street analysts forecast XAIR's revenue for 2025 to be $462,020,698, with the lowest XAIR revenue forecast at $449,407,028, and the highest XAIR revenue forecast at $474,634,368. On average, 1 Wall Street analysts forecast XAIR's revenue for 2026 to be $1,471,114,266, with the lowest XAIR revenue forecast at $1,471,114,266, and the highest XAIR revenue forecast at $1,471,114,266.

In 2027, XAIR is forecast to generate $3,138,641,387 in revenue, with the lowest revenue forecast at $3,138,641,387 and the highest revenue forecast at $3,138,641,387.

What is XAIR's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: XAIR) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of N/A.

What is XAIR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year XAIR price target, the average XAIR price target is $10.00, with the highest XAIR stock price forecast at $10.00 and the lowest XAIR stock price forecast at $10.00.

The Wall Street analyst predicted that Beyond Air's share price could reach $10.00 by Nov 14, 2024. The average Beyond Air stock price prediction forecasts a potential upside of 681.25% from the current XAIR share price of $1.28.

What is XAIR's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: XAIR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.